Filing Flows › Protalix BioTherapeutics (PLX) › Q1 2025
Protalix BioTherapeutics (PLX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Protalix BioTherapeutics (PLX) reported revenue of $10.1M for the first quarter 2025 (Q1 2025), +170% from a year earlier and -44% from the quarter before. Operating margin was -41.0%, net loss $3.6M (35.8% of revenue).
Protalix BioTherapeutics, Q1 2025: revenue $10.1M (+170% year over year), operating margin -41.0%, net loss $3.6M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.1M | -44% | +170% |
| Operating profit | −$4.1M | -157% | — |
| Net earnings | −$3.6M | -156% | — |
| Operating cash flow | −$5.1M | -227% | — |
What changed
Revenue was $10.1M in Q1 2025, up 170% year over year and down 44% from the previous quarter. GOODS was the largest line at 99% of revenue. GOODS added $6.3M year over year (up 172%), 99% of the total change.
Operating costs exceeded revenue by $4.1M, an operating margin of -41.0%. Total costs grew 66% against revenue growth of 170%. The fastest-growing cost line was Cost of revenue (+214%). The quarter ended with a net loss of $3.6M, after a profit of $6.5M the previous quarter.
Operating cash flow was −$5.1M. Non-cash charges added back $346K of depreciation and $540K of share-based compensation. Working capital and other items used $2.3M. Capital expenditures of $306K exceeded it, leaving free cash flow of −$5.4M.
Questions
What was Protalix BioTherapeutics' revenue in the first quarter 2025?
Protalix BioTherapeutics (PLX) reported revenue of $10.1M for the first quarter 2025 (Q1 2025), +170% from a year earlier and -44% from the quarter before.
Was Protalix BioTherapeutics profitable in the first quarter 2025?
Operating loss was $4.1M (-41.0% of revenue) and net loss $3.6M.